Novavax, Inc. today announced a new agreement that would maintain the U.S. public's access to Novavax's protein-based COBID-19 vaccine.
And this contract will support the U.S. government's continued efforts to make Novavax's vaccine available for free to states, jurisdictions, federal pharmacy partners, and federally qualified health centers.
Read More
